Capital Investment Services of America Inc. Purchases 41 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Capital Investment Services of America Inc. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,795 shares of the company’s stock after buying an additional 41 shares during the period. Capital Investment Services of America Inc.’s holdings in IDEXX Laboratories were worth $16,039,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Algert Global LLC increased its stake in shares of IDEXX Laboratories by 70.0% in the 2nd quarter. Algert Global LLC now owns 709 shares of the company’s stock valued at $345,000 after acquiring an additional 292 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $1,363,000. Czech National Bank grew its stake in shares of IDEXX Laboratories by 6.5% in the 3rd quarter. Czech National Bank now owns 16,766 shares of the company’s stock valued at $8,471,000 after buying an additional 1,028 shares during the period. GAMMA Investing LLC raised its stake in IDEXX Laboratories by 26.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,484 shares of the company’s stock worth $750,000 after buying an additional 314 shares during the period. Finally, Mather Group LLC. boosted its holdings in IDEXX Laboratories by 3.9% in the third quarter. Mather Group LLC. now owns 617 shares of the company’s stock worth $312,000 after acquiring an additional 23 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Up 0.8 %

IDEXX Laboratories stock opened at $468.55 on Thursday. The firm has a market capitalization of $38.37 billion, a price-to-earnings ratio of 45.18, a P/E/G ratio of 3.64 and a beta of 1.37. The firm has a 50 day simple moving average of $425.88 and a 200 day simple moving average of $453.51. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on IDXX shares. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday. Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $524.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.